There are many lysosomal proteases in the human body that can effectively cleave various peptide sequences. Scientists have developed and designed ADC linkers based on this, which are typically dipeptide or tetrapeptide linkers, such as ValCitPABC, a mature linker used in many approved or preclinical and clinically developed ADC drugs.